​​​​​

Photobiomodulation Equipment and Training - THOR Photomedicine

Select Region

Information contained on this page may not be appropriate for your region, please select your region from below. To navigate back to this region selector, please click "Region" in the footer.
Do More With A THOR
Lots of happy THOR customer testimonials
NovoTHOR Whole Body Light Pod

About THOR Photomedicine

On Star Trek when someone is injured, they are taken to sick bay where the doctor uses a laser to heal the patient instantly. We make those (just not quite as instant).

The treatment is called Photobiomodulation (PBM Therapy) previously known as Low Level Laser Therapy (LLLT) and is considered by many scientists to be "a new branch of medicine" (Dr Roberta Chow MD PhD).

Light (within certain parameters) can regenerate tissue, reduce inflammation and reduce pain. It does this by increasing cellular energy and reducing oxidative stress. These effects have been tested in over 700 clinical trials (RCT's) and thousands of laboratory studies and published in many leading journals including The Lancet, BMJ, Nature, PNAS, Spine, Muscle and Nerve, Pain, Stroke etc.

Dedicated private PBM clinics are being born every month to meet public demand for pain relief and the former head of tissue viability for Scotland Lydia Jack demonstrated that the laser paid for itself with the first patient she treated.

Already THOR has over 5,000 customers in pioneering clinics and hospitals in more than 70 countries and is the only company with FDA, CE, TGA and NATO clearance, and we are also listed on GSA, and eCAT in the United States for government purchases.

VISION

Photobiomodulation (PBM) in every department of every hospital.

MISSION

To heal and relieve pain.

VALUES

Our decisions and actions must work for all stakeholders;

OBJECTIVE

To establish Photobiomodulation as a standard of care for
10 diseases in
10 countries in
10 years (end of 2030)

James Carroll, Founder, CEO at THOR Photomedicine Ltd

THOR Photomedicine Ltd is privately owned by founder and CEO James Carroll
James Carroll LinkedIn Profile
James Carroll papers


THOR Photomedicine Ltd is an ISO 13485:2016 certified medical device company.

The THOR LX2.3 Photobiomodulation system has a medical CE mark (EC certificate). It is indicated for oral mucositis, tendinopathies, joint pain, neck pain and back pain for marketing in the UK, EU and Australia.

The THOR LX2.3 Photobiomodulation system is also FDA Cleared for marketing in the United States for: Temporary increase in local blood circulation, temporary relief of minor muscle and joint aches, pains and stiffness and relaxation of muscles; for muscle spasms, and minor pain and stiffness associated with arthritis.

Excluding the THOR LED Helmet, THOR LX2 and NovoTHOR systems are manufactured under conditions fulfilling the quality system requirements of Annex II, excluding (4), of the directive 93/42/EEC as amended and satisfy the applicable international harmonised standards.

Quality certificates

[top]



OUR CUSTOMERS INCLUDE:
Our customers include: Harvard Medical School, Massachusetts General Hospital, British Army, RAF, Royal Navy, Team GB, Manchester United, MIT, Harvard School of Public Health, Cedars Sinai, City of Hope, USUHS
THOR Customers

THOR Photomedicine Ltd is an ISO 13485:2016 certified medical device company.

The THOR LX2.3 Photobiomodulation system has a medical CE mark (EC certificate). It is indicated for oral mucositis, tendinopathies, joint pain, neck pain and back pain for marketing in the UK, EU and Australia.

The THOR LX2.3 Photobiomodulation system is also FDA Cleared for marketing in the United States for: Temporary increase in local blood circulation, temporary relief of minor muscle and joint aches, pains and stiffness and relaxation of muscles; for muscle spasms, and minor pain and stiffness associated with arthritis.

Excluding the THOR LED Helmet, THOR LX2 and NovoTHOR systems are manufactured under conditions fulfilling the quality system requirements of Annex II, excluding (4), of the directive 93/42/EEC as amended and satisfy the applicable international harmonised standards.

Positive systematic reviews published by:

The British Medical Journal (BMJ), The Lancet, the International Association for the Study of Pain (IASP), the World Health Organisation (WHO), the Multinational Association for Supportive Care in Cancer (MASCC), the European Society for Medical Oncology (ESMO)

Appropriate regulatory clearance or approvals include:

Quality certificates

​​​​​